Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management—Single-Center Experience

被引：40

作者：

Bhatia R. ^{[1
]}

Ravulapati S. ^{[2
]}

Befeler A. ^{[1
]}

Dombrowski J. ^{[3
]}

Gadani S. ^{[4
]}

Poddar N. ^{[2
]}

机构：

[1] Division of Gastrointestinal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, 63110, MO

[2] Division of Hematology, Oncology, Bone Marrow Transplant and Cellular Therapies, Saint Louis University School of Medicine, 3655 Vista Avenue, 3rd Floor, St. Louis, 63110, MO

[3] Department of Radiation Oncology, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, 63110, MO

[4] Department of Radiology, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, 63110, MO

来源：

Journal of Gastrointestinal Cancer | 2017年 / 48卷 / 4期

关键词：

Bone metastases; Carcinoma;

D O I：

10.1007/s12029-017-9998-6

中图分类号：

学科分类号：

摘要：

Background: Hepatocellular carcinoma (HCC) represents one of the most common causes of cancer-related deaths worldwide, with rising incidence in the USA. Bone metastases with HCC, in particular, have an extremely poor prognosis. We present prevalence, treatment, and survival of patients with bone and more specifically spinal metastases from HCC. Methods: A retrospective analysis was done at a single tertiary care institution of patients with bone metastases from HCC between January 2005 and December 2015. Results: Among 1017 patients with HCC, 20 were found to have bone metastases of which 11 had spinal metastases. Seventeen (85%) were male, with median age of 58 years at time of HCC diagnosis. Systemic chemotherapy and sorafenib were used in 12 (60%) patients, and 12 (60%) received radiation therapy. Among patients who did not receive therapy, median survival was 76 days. Median survival after diagnosis of metastasis in patients on sorafenib and radiation were 106 and 100 days, respectively. Conclusion: Bone metastases in HCC are very rare and aggressive. Due to its rarity, optimal treatment strategies are not well defined. Early diagnosis is important for optimal therapy and improved survival. © 2017, Springer Science+Business Media, LLC.

引用

页码：321 / 325

页数：4

共 16 条

[1]

Suresh V.S., Babu K.G., Lokanatha D., Bapsy P.P., Ramachandra C., Rajshekar H., Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment, J Cancer Res Therapy June, 4, (2008)

[2]

Clark H.P., Carson W.F., Kavanagh P.V., Et al., Staging and current treatment of hepatocellular carcinoma, Radiographics, 25, pp. S3-S23, (2005)

[3]

Lin S., Hoffman K., Schemer P., Treatment of hepatocellular carcinoma: a systemic review, Liver Cancer, pp. 144-158, (2012)

[4]

Okazaki N., Yoshino M., Yoshida T., Hirohashi S., Kishi K., Shimosato Y., Bone metastases in hepatocellular carcinoma, Cancer, 55, pp. 1991-1994, (1985)

[5]

Brown R.S., Kumar K.S., Russo M.W., Et al., Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in united network for organ sharing status 2A patients, Liver Transpl, 8, 3, pp. 278-284, (2002)

[6]

Mazzaferro V., Regalia E., Doci R., Et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, pp. 693-699, (1996)

[7]

He J., Zeng Z.C., Tang Z.Y., Et al., Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy, Cancer, 115, pp. 2710-2720, (2009)

[8]

Fukutomi M., Yokota M., Chuman H., Harada H., Zaitsu Y., Funakoshi A., Et al., Increased incidence of bony metastases in hepatocellular carcinoma, Eur J Gastroenterol Hepatol, 13, pp. 1083-1088, (2001)

[9]

Tamaki K., Shimizu I., Urata M., Et al., A patient with spinal metastasis from hepatocellular carcinoma discovered from neurological findings, World J Gastroenterol, 13, 19, pp. 2758-2760, (2007)

[10]

Zhu A., Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?, The Oncologist July, 11, 7, pp. 790-800, (2006)

← 1 2 →